Alps Group Inc(ALPS)

Biotechnology · Kuala Lumpur, WP

$0.39-0.01 (-3.58%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T21:00:36.520Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:00:36.520Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 64,180,607
Total debt · period ending 2026-03-31: N/A
Cash · period ending 2026-03-31: N/A
TTM operating income · period ending 2025-09-30: N/A

FMP input reference: 473da95602fdb42a5f780e5c02853506da999e38a33e04168dea7648cb5c925f

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALPS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

ALPS Competitors' EV/EBIT Ratio

ALPS

Alps Group Inc

Current

Market Cap

$64.18M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRX

Pliant Therapeutics, Inc.

vs ALPS

Market Cap

$63.78M

EV/EBIT Ratio

N/A

TTM Avg

31.50x

3Y Avg

31.50x

5Y Avg

31.50x

INCR

InterCure Ltd.

vs ALPS

Market Cap

$63.02M

EV/EBIT Ratio

N/A

TTM Avg

9.73x

3Y Avg

23.03x

5Y Avg

21.55x

HRTX

Heron Therapeutics, Inc.

vs ALPS

Market Cap

$62.78M

EV/EBIT Ratio

N/A

TTM Avg

237.48x

3Y Avg

237.48x

5Y Avg

237.48x

RNXT

RenovoRx, Inc.

vs ALPS

Market Cap

$62.62M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XBIT

XBiotech Inc.

vs ALPS

Market Cap

$65.85M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CING

Cingulate Inc.

vs ALPS

Market Cap

$65.86M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GOSS

Gossamer Bio, Inc.

vs ALPS

Market Cap

$65.87M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IBIO

iBio, Inc.

vs ALPS

Market Cap

$67.52M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs ALPS

Market Cap

$60.42M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Alps Group Inc (ALPS)	$64.18M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.78M	N/A	31.50x	31.50x	31.50x
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	9.73x	23.03x	21.55x
Heron Therapeutics, Inc. (HRTX)vs ›	$62.78M	N/A	237.48x	237.48x	237.48x
RenovoRx, Inc. (RNXT)vs ›	$62.62M	N/A	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.85M	N/A	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$65.86M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$65.87M	N/A	N/A	N/A	N/A
iBio, Inc. (IBIO)vs ›	$67.52M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.42M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

ALPS EV/EBIT Ratio Metrics

ALPS Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics